{"id":135778,"date":"2026-09-24T16:29:42","date_gmt":"2026-09-24T16:29:42","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/135778\/"},"modified":"2026-09-24T16:29:42","modified_gmt":"2026-09-24T16:29:42","slug":"roche-ionis-rna-drug-scores-in-kidney-disease-study-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/135778\/","title":{"rendered":"Roche, Ionis RNA drug scores in kidney disease study"},"content":{"rendered":"\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily <a href=\"https:\/\/www.biopharmadive.com\/signup\/?utm_campaign=Yahoo-Licensed-Content&amp;utm_source=yahoo&amp;utm_medium=referral\" data-ylk=\"slk:BioPharma%20Dive%20newsletter;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;BioPharma Dive newsletter&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">BioPharma Dive newsletter<\/a>.  <\/p>\n<p>        Dive Brief:            <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Roche and Ionis Pharmaceuticals said Wednesday their experimental drug for the kidney disorder IgA nephropathy <a href=\"https:\/\/www.roche.com\/media\/releases\/med-cor-2026-09-23b\" data-ylk=\"slk:succeeded%20in%20a%20Phase%203%20clinical%20trial;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;succeeded in a Phase 3 clinical trial&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">succeeded in a Phase 3 clinical trial<\/a>, hitting its main goal at an interim data check.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Called sefaxersen, the drug led to &#8220;statistically significant and clinically meaningful improvements&#8221; in the amount of protein in participants&#8217; urine, an important marker of kidney health, the companies said. They didn&#8217;t provide specific details, but said the data will be presented at an upcoming medical meeting and shared with regulators. They&#8217;ll also continue monitoring enrollees for two years to monitor changes in kidney function.\u00a0  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">If approved by regulators, sefaxersen would face competition from multiple drugs launched over the last few years for IgA nephropathy, among them <a href=\"https:\/\/www.biopharmadive.com\/news\/novartis-fabhalta-iga-nephropathy-study-results\/802943\/\" data-ylk=\"slk:Novartis&#039;%20Fabhalta;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;Novartis&#039; Fabhalta&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Novartis&#8217; Fabhalta<\/a>. Drugmakers have priced those therapies, which could slow disease progression and help patients avert expensive kidney dialysis or transplants, at around $400,000 to $500,000 a year.  <\/p>\n<p>                   Dive Insight:          <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">IgA nephropathy is an autoimmune disorder that occurs when rogue antibodies enter the kidneys and form clumps that cause inflammation and impede organ function. It&#8217;s recently become a hotbed for drug research, thanks to a better understanding of the disease&#8217;s biology and the need for better treatments.\u00a0\u00a0  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Sefaxersen acts on a similar biological pathway as Fabhalta. That target, &#8220;complement factor B,&#8221; drives inflammation and kidney tissue damage in IgA nephropathy. Fabhalta directly binds to that protein, whereas sefaxersen, an antisense oligonucleotide, suppresses its production by binding to a messenger molecule in the liver.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Roche and Ionis are pitching sefaxersen as a more convenient alternative to Fabhalta. Their drug is self-injected once monthly, while Fabhalta is a twice-daily pill. The shot emerged from <a href=\"https:\/\/www.biopharmadive.com\/news\/roche-ionis-focusing-on-eye-disease-through-new-deal\/539357\/\" data-ylk=\"slk:one%20of%20multiple%20partnerships;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;one of multiple partnerships&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">one of multiple partnerships<\/a> between the two companies that has also seen them collaborate on <a href=\"https:\/\/www.biopharmadive.com\/news\/roche-ionis-alzheimers-huntingtons-neuroscience-deal\/694904\/\" data-ylk=\"slk:experimental%20drugs%20for%20Huntington&#039;s%20and%20Alzheimer&#039;s%20disease;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;experimental drugs for Huntington&#039;s and Alzheimer&#039;s disease&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">experimental drugs for Huntington&#8217;s and Alzheimer&#8217;s disease<\/a>.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">But sefaxersen, if approved, would have other competitors to deal with too. Since late last year, the Food and Drug Administration has granted accelerated clearances from <a href=\"https:\/\/www.biopharmadive.com\/news\/otsuka-accelerated-approval-voyxact-IgAN\/806543\/\" data-ylk=\"slk:Otsuka%20Pharmaceutical;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;Otsuka Pharmaceutical&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Otsuka Pharmaceutical<\/a> and <a href=\"https:\/\/www.biopharmadive.com\/news\/vera-fda-approve-trutakna-IgAN-kidney-disease-atacicept\/824620\/\" data-ylk=\"slk:Vera%20Therapeutics;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;Vera Therapeutics&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">Vera Therapeutics<\/a> that act on different protein targets. Another <a href=\"https:\/\/www.biopharmadive.com\/news\/vertex-povetacicept-iga-nephropathy-study-results\/814253\/\" data-ylk=\"slk:drug%20from%20Vertex%20Pharmaceuticals;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;drug from Vertex Pharmaceuticals&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">drug from Vertex Pharmaceuticals<\/a> could soon follow.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">IgAN remains a &#8220;large but competitive market,&#8221; spanning a &#8220;multitude of targets and dosing regimens,&#8221; wrote William Blair analyst Myles Minter. Sefaxersen&#8217;s monthly dosing via an autoinjector is &#8220;relatively competitive,&#8221; with only Vertex&#8217;s drug having a similar profile. But the data presentation will be crucial in assessing the drug&#8217;s comparative benefits and safety, Minter added.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Sefaxersen is one of several pipeline assets identified by RBC Capital Markets analyst Trung Huynh as &#8220;underappreciated&#8221; by Roche investors. The Swiss pharma giant&#8217;s base business is growing slowly as it <a href=\"https:\/\/www.biopharmadive.com\/news\/roche-q1-2026-earnings-giredestrant-obesity-drugs\/818300\/\" data-ylk=\"slk:absorbs%20patent%20expirations;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;absorbs patent expirations&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">absorbs patent expirations<\/a> for key products. But in a recent research note, Huynh contended that sefaxersen, along with the <a href=\"https:\/\/www.biopharmadive.com\/news\/roche-giredestrant-serd-adjuvant-breast-cancer-study-results\/805768\/\" data-ylk=\"slk:breast%20cancer%20drug%20giredestrant;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;breast cancer drug giredestrant&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">breast cancer drug giredestrant<\/a>\u00a0and the <a href=\"https:\/\/www.biopharmadive.com\/news\/roche-fenebrutinib-relapsed-multiple-sclerosis-fenhance-2-results\/813471\/\" data-ylk=\"slk:multiple%20sclerosis%20treatment%20fenebrutinib;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;multiple sclerosis treatment fenebrutinib&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">multiple sclerosis treatment fenebrutinib<\/a>, could boost earnings in the years ahead.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">An approval would also provide a boost for Ionis, which has seen its share price pressured <a href=\"https:\/\/www.biopharmadive.com\/news\/novartis-ionis-pelacarsen-lpa-horizon-study-results-fail\/829736\/\" data-ylk=\"slk:by%20multiple%20setbacks;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;by multiple setbacks&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">by multiple setbacks<\/a> <a href=\"https:\/\/www.biopharmadive.com\/news\/astrazeneca-ionis-eplontersen-nejm-cardio-ttransform-results\/829057\/\" data-ylk=\"slk:this%20year;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;this year&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">this year<\/a>. Ionis is due up to $400 million in milestone payments related to sefaxersen and would get sales royalties if the drug is cleared.  <\/p>\n","protected":false},"excerpt":{"rendered":"This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free&hellip;\n","protected":false},"author":2,"featured_media":135779,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[4396,7997,8512,28740,65507,65508,6646,51371,134,28743],"class_list":["post-135778","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-drug","tag-experimental-drug","tag-iga-nephropathy","tag-ionis-pharmaceuticals","tag-kidney-dialysis","tag-kidney-disorder","tag-kidney-function","tag-kidney-health","tag-roche","tag-vertex-pharmaceuticals"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117326968633986900","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/135778","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=135778"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/135778\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/135779"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=135778"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=135778"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=135778"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}